Prosecution Insights
Last updated: July 17, 2026
Application No. 17/821,007

Cyanine dyes and their usage for in vivo staining of microorganisms and other living cells

Final Rejection §102
Filed
Aug 19, 2022
Priority
Aug 20, 2021 — EU 21192451.9
Examiner
ROZOF, TIMOTHY R
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Philipps-Universität Marburg
OA Round
2 (Final)
73%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
697 granted / 960 resolved
+12.6% vs TC avg
Strong +24% interview lift
Without
With
+24.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
49 currently pending
Career history
992
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
23.8%
-16.2% vs TC avg
§102
27.9%
-12.1% vs TC avg
§112
21.2%
-18.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 960 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This is a response to Applicant’s communication filed on February 27, 2026. Application No. 17/821,007, filed August 19, 2022, is a U.S. Nonprovisional application, which claims foreign priority to European Patent Office application No. EP21192451.9, filed August 20, 2021. Claims 1-4 and 10-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention. Claim 7 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species. Claims 5, 6, 8 and 9 are examined below. Election/Restrictions Please note that upon finding allowable subject matter in the elected invention of Group II, the nonelected inventions of Groups I and III (claims 1-4 and 11) are not subject to rejoinder as these claims are not limited by the elected invention of Group II (i.e., the cyanine dyes of claims 5-9). In order to advance prosecution of the application to allowance, it is suggested that Applicant cancel claims 1-4 and 11 in response to this office action. Rejection Maintained Claim Rejections - 35 USC § 102(a)(1) The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. The rejection of claims 5, 6, 8, and 9 under 35 U.S.C. 102(a)(1) as being anticipated by Vazquez Vazquez et al., EP3,572,468 (publ’d November. 27, 2019) (cited on the November 22, 2022, IDS) is maintained for reasons made of record. Applicant amended formula (I) of claim 5 so that “n” is limited to 1 or 2 from 1 to 3. The elected species reads on formula (I), where n is 2. Vazquez Vazquez discloses the elected species 6-TramTO-3, as follows: PNG media_image1.png 237 311 media_image1.png Greyscale (Vazquez Vazquez et al., EP ‘468, p. 12, para. [0057].) Conclusion No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIMOTHY R ROZOF whose telephone number is (571)270-5992. The examiner can normally be reached Monday - Friday, 9:00 a.m. -5:00 p.m.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TIMOTHY R ROZOF/ Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Aug 19, 2022
Application Filed
Oct 31, 2025
Non-Final Rejection mailed — §102
Feb 27, 2026
Response Filed
May 05, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679843
PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS
2y 10m to grant Granted Jul 14, 2026
Patent 12661359
THERAPEUTIC COMBINATIONS OF ROSUVASTATIN AND RESMETIROM FOR THE TREATMENT OF LIVER DISORDERS OR LIPID DISORDERS
2y 10m to grant Granted Jun 23, 2026
Patent 12662462
SALTS OF PYRIDINYLMETHYLENEPIPERIDINE DERIVATIVES AND USES THEREOF
2y 12m to grant Granted Jun 23, 2026
Patent 12649744
N-(PYRIDIN-2-YL)-6,7,8,9-TETRAHYDRO-5H-5,8-EPIMINOCYCLOHEPTA[C]PYRIDINE-10-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS GPR65 MODULATORS FOR THE TREATMENT OF CANCER
2y 12m to grant Granted Jun 09, 2026
Patent 12649748
WEE1 INHIBITOR AND USE THEREOF
2y 8m to grant Granted Jun 09, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
73%
Grant Probability
97%
With Interview (+24.0%)
2y 0m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 960 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month